若生智能
Drug Database
CE

cefaclor (Raniclor / Raniclor)

✓ Approved

Ranbaxy Laboratories Limited · 小分子 · 小分子

什么是 cefaclor？

cefaclor 是一种小分子，由Ranbaxy Laboratories Limited研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Raniclor, Raniclor
公司Ranbaxy Laboratories Limited
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Ranbaxy Laboratories Limited

治疗适应症

cefaclor 针对 6 个适应症，涉及 3 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsLower respiratory tract infection✓ Approved
Infections and infestationsOtitis media✓ Approved
Infections and infestationsTonsillitis✓ Approved
Infections and infestationsUrinary tract infection✓ Approved
Respiratory, thoracic and mediastinal disordersTonsillar inflammation✓ Approved

注册免费账户还可查看另外 1 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026-07-30

Three-dimensional printing as a transformative platform for patient-centric pediatric drug delivery: technologies, formulation strategies and clinical translation.

Phadte Padmadip P, Jeedigunta Mythili Krishna MK, Rao Gopalkrishna G, Chellampillai Bothiraja B

Pediatric patients require age-appropriate dosage forms because developmental differences in physiology, pharmacokinetics and swallowing ability can significantly affect therapeutic outcomes. Conventional dosage forms are often unsuitable for children and practices such as tablet splitting, crushing or extemporaneous preparation may lead to dose inaccuracy, altered stability, poor palatability and reduced adherence. These limitations highlight the need for innovative formulation strategies that provide precise dosing while improving acceptability and therapeutic effectiveness. In this context, three-dimensional (3D) printing has emerged as a promising platform for personalized pediatric drug delivery. This review critically examines recent advances in 3D printing technologies for pediatric drug delivery and provides a formulation-focused and translational perspective by integrating pediatric therapeutic needs with technology selection, polymer considerations and dosage form design flexibility. A comprehensive literature review was conducted to evaluate recent developments in pediatric pharmaceutical applications of 3D printing. Major technologies including fused deposition modeling, semi-solid extrusion, binder jet printing and inkjet printing were assessed with respect to formulation design, polymer selection, drug-polymer compatibility and pediatric suitability. Particular emphasis was placed on taste-masking approaches, personalized dosing capability and dosage adaptability for different pediatric age groups. Three-dimensional printing enables fabrication of diverse pediatric-friendly dosage forms including chewable gummies, mini-tablets, orodispersible films and confectionery-like formulations. Published studies demonstrated improved dose precision, effective taste masking, customizable drug release profiles and enhanced patient acceptability. Regulatory approval of Spritam further supports the clinical feasibility of this technology. However, challenges remain regarding printer calibration, reproducibility, limited pharmaceutical-grade printable materials, long-term stability and regulatory harmonization. Three-dimensional printing represents an important advancement in patient-centric pediatric pharmacotherapy by enabling precise control over dose, geometry, release kinetics and sensory attributes. This review highlights its practical potential and translational readiness for pediatric healthcare.

PMID 42530696
阅读全文 →
PubMedParasites & vectors2026-07-28

Efficacy of a single oral administration of a formulation of fluralaner, moxidectin and pyrantel (BRAVECTO® TriUNO) in dogs for the treatment and prevention of angiostrongylosis.

Rohdich Nadja N, Chiummo Rafael R, Zschiesche Eva E, Raulf Marie-Kristin MK et al.

Four studies investigated the efficacy of fluralaner/moxidectin/pyrantel chewable tablets (Bravecto® TriUNO) in preventing and treating canine angiostrongylosis; one study also included a formulation of fluralaner/milbemycin oxime. Studies included eight or 10 dogs/group. In Studies 1 and 2 (prevention), dogs inoculated with third-stage larvae of Angiostrongylus vasorum on day - 31 or - 28 were randomized to groups by sex and body weight; in Studies 3 and 4 (treatment) by faecal first-stage larvae counts at approximately 8 weeks post-inoculation (PI). All studies included an untreated control group (CG). Study 1 included three groups treated with formulations of moxidectin/fluralaner/pyrantel; minimum moxidectin doses 0.0125, 0.025 or 0.055 mg/kg. The formulation with moxidectin at 0.025 mg/kg, 99.0% effective in preventing establishment of infection, was adopted as the investigational veterinary product (IVP) for the following studies. Study 2 included a group treated with either the IVP or a combination of fluralaner (10 mg/kg) with milbemycin oxime (0.75 mg/kg) (IVP-2). In all studies, the IVP was administered once on day 0; in Study 2, IVP-2 was administered on days 0, 31, 62 and 93. In Study 1, efficacy was determined by reductions in geometric mean necropsy worm counts approximately 33 days post-treatment versus mean CG counts, in the other studies by reductions in mean faecal L1 counts. Study 2 assessed pulmonary changes via thoracic computed tomography. Respiratory signs and serological antibody responses were monitored. In Study 1, all moxidectin doses exceeded 90% efficacy. In Study 2, IVP efficacy (one treatment) at 62 days was 100.0%; IVP-2 (four treatments) efficacy was 99.8% at 124 days. Respiratory signs were absent or lower in IVP-treated than CG dogs. In Studies 3 and 4, IVP efficacy was 100% by 3 and 4 weeks post-treatment, respectively. In all studies, lungworm count reductions in the IVP groups were statistically significant (P < 0.0001) versus the CG. Serology confirmed A. vasorum infections in all control and IVP-2-treated dogs, and absence of infections in IVP-treated dogs. Treatments were well tolerated. A single treatment with Bravecto TriUNO is highly effective in preventing angiostrongylosis and eliminating established A. vasorum infections. Infection-related lung pathology was reduced in treated dogs.

PMID 42509566
阅读全文 →
PubMedThe Lancet. Infectious diseases2026-07-23

Efficacy, safety, and acceptability of a child-friendly, chewable formulation of oxantel pamoate versus mebendazole for Trichuris spp infections in children aged 2-12 years in Tanzania: a randomised, single-blind, phase 2 trial.

Jeanguenat Hannah H, Schnoz Annina A, Amour Amour Khamis AK, Ahmada Ahmada Ali AA et al.

Trichuriasis, caused by the nematodes Trichuris trichiura and Trichuris incognita, affects an estimated 267 million people worldwide, particularly children. Currently available treatments (albendazole and mebendazole) fail to achieve sufficient cure rates. Oxantel pamoate is a drug known for its trichuricidal activity. In this study, we aimed to assess whether a newly developed, child-friendly oxantel pamoate formulation is superior to mebendazole, one of WHO's recommended treatments for trichuriasis. We conducted a randomised, single-blind, phase 2 trial in a primary school and nursery on Pemba Island, Tanzania. Children aged 2-12 years diagnosed with Trichuris spp infection were randomly assigned to receive single-dose oxantel pamoate (20 mg/kg bodyweight as chewable 250 mg tablets), multiple-dose oxantel pamoate (20 mg/kg bodyweight as chewable 250 mg tablets on 3 consecutive days), or single-dose mebendazole (500 mg as one chewable tablet). Participants were randomly assigned in a 1:1:1 ratio by use of a computer-generated randomisation code stratified by baseline infection intensity and age. Participants, study physicians, and laboratory technicians were masked to treatment allocation; no placebo treatment was added to match procedures across groups. The primary endpoint was the cure rate, assessed by Kato-Katz 14-21 days after treatment, and a secondary endpoint was egg reduction rate, assessed in the available case population (all randomly assigned participants who provided any follow-up efficacy data). Safety analysis included all randomly assigned participants who received at least one dose of study treatment. The trial is registered at ClinicalTrials.gov (NCT06720259) and is completed. Between April 16 and May 28, 2025, we recruited 166 participants, of whom 163 were randomly assigned to treatment groups (81 female, 82 male). Of these, 55 received single-dose oxantel pamoate, 54 multiple-dose oxantel pamoate, and 54 single-dose mebendazole; one participant in the multiple-dose oxantel pamoate group was lost to follow-up. The cure rates were 18·2% (95% CI 9·1-30·9) for the single-dose oxantel pamoate group, 64·2% (49·8-76·9) for multiple-dose oxantel pamoate, and 7·4% (2·1-17·9) for single-dose mebendazole. Logistic regression showed that single-dose oxantel pamoate was not significantly superior to single-dose mebendazole in terms of cure rate (odds ratio 0·36, 95% CI 0·09-1·16; p=0·10). However, the egg reduction rate was superior for single-dose oxantel pamoate compared with mebendazole (a difference of 10·0 percentage points [95% CI 2·5-21·3] between 96·2% [93·0-98·1] and 86·3% [75·0-92·9], respectively). Oxantel pamoate was well tolerated, with abdominal pain reported as the main adverse event. Our study did not provide sufficient evidence of superiority in terms of cure rate for single-dose oxantel pamoate over single-dose mebendazole. However, the superiority in egg reduction rates seems to corroborate the higher efficacy observed in previous phase 2 studies and supports phase 3 development towards regulatory approval. European Union. For the Swahili translation of the abstract see Supplementary Materials section.

PMID 42486129
阅读全文 →
PubMedBJGP open2026-07-16

Understandability of statin patient information leaflets in the UK: a mixed-methods cross-sectional evaluation.

Rao Diya D, Dickson Jon M JM, Sudbury Mia M, Dixon William W et al.

Statins are the UK's most prescribed medicine and are used more in deprived populations. Patient Information Leaflets (PILs) included in medication packaging may support safe, effective use, but only if they are understandable. Guidance states PILs should have a reading age of ≤13-years, and regulators require that ≥80% of patients answer comprehension questions correctly on them when 'user tested'. To provide the first independent evaluation of the readability and comprehension of UK statin PILs. Study 1: Cross-sectional analysis of the reading age of 39/40 of the UK's approved statin PILs. Study 2: Cross-sectional survey with a representative sample of 517 UK adults aged 40-74. Study 1: Reading age was assessed using four readability formulas, with additional scores calculated after adjusting for potentially familiar technical terms. Study 2: Two PILs (atorvastatin [MSN] and rosuvastatin [Ranbaxy]) were randomly selected and user tested with participants. They answered eight comprehension questions per PIL; responses were double-scored. Study 1: No PIL met the recommended reading age. Median reading age was 15.9 years (15.0 after adjustment). Atorvastatin PILs were least readable. Study 2: Key messages were poorly understood; for atorvastatin, 5/8 items met the≥80% criterion; for rosuvastatin, 2/8 met it. Key safety and use messages were frequently misunderstood. UK statin PILs do not meet recommended readability or comprehension standards and are likely to be difficult to understand for many users. Improving clarity and usability is essential to support equitable understanding and safe, informed long-term statin use.

PMID 42457226
阅读全文 →
PubMedFrontiers in dental medicine2026-07-16

Clinical and enzymatic evaluation of the effect of dietary vitamin C on orthodontic tooth movement.

Pulikkottil Sunny Naveen N, Ravi M S MS

To evaluate the effect of dietary vitamin C supplementation on the rate of orthodontic tooth movement during canine retraction by comparing individuals receiving supplementation with those who are not. Additionally, to analyze changes in selected enzymatic biomarkers in the gingival crevicular fluid (GCF). This study included 28 patients who underwent orthodontic treatment followed by first premolar extraction and levelling. Participants were divided into two groups: Group I received dietary vitamin C supplementation (500 mg chewable tablets), while Group II served as controls without supplementation. Canine retraction was carried out using NiTi closed coil springs delivering 150 g force with absolute anchorage provided by mini-implants, and digital scans were recorded at R0(before retraction) and R1(75 days). The rate of canine retraction was calculated as the distance moved per time. GCF was collected at baseline (T0), before retraction (T1), and after 75 days (T2) and analyzed for alkaline phosphatase and acid phosphatase levels using ELISA. The vitamin C group demonstrated significantly greater maxillary canine retraction compared to controls, with mean values of (3.20 ± 0.84 mm) vs. (1.96 ± 0.60 mm) in males and (2.86 ± 0.38 mm) vs. (1.73 ± 0.31 mm) in females. Alkaline phosphatase and Acid phosphatase levels increased significantly over time in both groups, with a greater rise in the vitamin C group. Dietary vitamin C supplementation significantly accelerated canine retraction and enhanced bone remodeling enzyme activity during orthodontic treatment.

PMID 42459823
阅读全文 →
PubMedThe American journal of case reports2026-07-09

Anterior ST-Segment Elevation Myocardial Infarction Shortly After Cefaclor Exposure: A Case Report Highlighting Kounis Syndrome as a Differential Diagnosis.

Zuo Quan Q, Zhu Yue Y, Wang Zhiwei Z, Ge Tao T

BACKGROUND Kounis syndrome is an acute coronary syndrome associated with allergic or hypersensitivity reactions, but establishment of causality is difficult when objective allergy-related tests are unavailable during emergency treatment. This report describes anterior ST-segment elevation myocardial infarction (STEMI) occurring shortly after cefaclor exposure and highlights the diagnostic limitations of attributing the event to hypersensitivity in routine emergency clinical practice. CASE REPORT A 61-year-old man with a history of positive penicillin skin testing, but no prior penicillin administration, developed severe chest pain approximately 1 hour after self-administration of oral cefaclor for respiratory symptoms. He had no rash, urticaria, wheezing, angioedema, oropharyngeal edema, hypotension, or dyspnea; no prehospital antihistamines, corticosteroids, or epinephrine were administered. Electrocardiography showed ST-segment elevation in V2 to V6, and emergency coronary angiography demonstrated 90% proximal left anterior descending artery stenosis with Thrombolysis in Myocardial Infarction grade II flow. Primary percutaneous coronary intervention restored grade III flow and relieved symptoms. High-sensitivity cardiac troponin I increased from 0.57 to 1.10 ng/mL and peaked at 3.92 ng/mL at 15 hours. Serum tryptase, histamine, total and specific IgE, and intracoronary imaging were not obtained. The Naranjo score was 2, indicating a possible adverse drug reaction. CONCLUSIONS The temporal association prompted consideration of Kounis syndrome, but severe fixed coronary stenosis makes coincidental plaque-related STEMI a major alternative diagnosis. Early allergy biomarker sampling and careful causal assessment are important in similar cases.

PMID 42421293
阅读全文 →

注册免费账户还可查看另外 2756 篇文献

免费注册查看全部文献 →

了解更多cefaclor